Lyudmila Bazhenova Selected Research

Lyudmila Bazhenova Research Topics

Disease

30	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 10/2022 - 04/2010
25	Neoplasms (Cancer) 10/2022 - 01/2013
15	Lung Neoplasms (Lung Cancer) 09/2021 - 04/2011
6	Disease Progression 09/2021 - 02/2006
4	Neoplasm Metastasis (Metastasis) 01/2022 - 04/2014
4	Circulating Neoplastic Cells 02/2015 - 02/2012
3	Diarrhea 01/2022 - 10/2019
2	Adenocarcinoma of Lung 03/2022 - 09/2017
2	Exanthema (Rash) 01/2022 - 01/2018
2	Hypertension (High Blood Pressure) 01/2020 - 10/2019
1	Colorectal Neoplasms (Colorectal Cancer) 10/2022
1	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 03/2022
1	Body Weight (Weight, Body) 01/2022
1	Interstitial Lung Diseases (Interstitial Lung Disease) 01/2022
1	Neutropenia 01/2022
1	Hyperglycemia 02/2021
1	Vomiting 02/2021
1	Hyponatremia 01/2020
1	Lymphopenia (Lymphocytopenia) 01/2020
1	Proteinuria 10/2019
1	Pneumonia (Pneumonitis) 01/2019
1	Epilepsy (Aura) 01/2019
1	Fatigue 01/2018
1	Carcinogenesis 01/2018
1	Acne Vulgaris 01/2018
1	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2018
1	Melanoma (Melanoma, Malignant) 11/2017
1	Pulmonary Embolism 12/2016
1	Thrombocytopenia (Thrombopenia) 12/2016
1	Thrombosis (Thrombus) 02/2015
1	Venous Thromboembolism 02/2015
1	Genomic Instability 01/2015
1	Hypersensitivity (Allergy) 12/2014
1	Mesothelioma 12/2014
1	Malignant Mesothelioma 12/2014

Drug/Important Bio-Agent (IBA)

8	ErbB Receptors (EGF Receptor)IBA 03/2022 - 03/2015
6	Phosphotransferases (Kinase)IBA 10/2022 - 04/2010
6	Biomarkers (Surrogate Marker)IBA 01/2021 - 01/2013
5	Tyrosine Kinase InhibitorsIBA 03/2022 - 12/2016
4	PlatinumIBA 01/2022 - 02/2021
3	TropomyosinIBA 01/2022 - 01/2018
3	Pharmaceutical PreparationsIBA 01/2022 - 03/2015
3	Immune Checkpoint InhibitorsIBA 01/2021 - 11/2017
3	osimertinibIBA 01/2019 - 12/2016
2	adagrasibIBA 10/2022 - 01/2022
2	entrectinibIBA 05/2022 - 01/2022
2	Proteins (Proteins, Gene)FDA Link 03/2022 - 07/2009
2	B7-H1 AntigenIBA 01/2022 - 01/2017
2	amivantamab-vmjwIBA 01/2022 - 01/2022
2	NivolumabIBA 09/2021 - 01/2021
2	Pemetrexed (MTA)FDA Link 02/2021 - 12/2014
2	Paclitaxel (Taxol)FDA LinkGeneric 02/2021 - 01/2021
2	selpercatinibIBA 01/2021 - 01/2020
2	Alanine Transaminase (SGPT)IBA 01/2020 - 12/2016
2	Erlotinib Hydrochloride (CP 358,774)FDA Link 10/2019 - 01/2017
2	Biological ProductsIBA 01/2019 - 04/2014
2	AntibodiesIBA 01/2018 - 08/2014
2	Circulating Tumor DNAIBA 10/2017 - 09/2017
2	Keratins (Keratin)IBA 01/2017 - 08/2014
1	c-Mer Tyrosine KinaseIBA 10/2022
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 10/2022
1	sitravatinibIBA 10/2022
1	pembrolizumabIBA 01/2022
1	Axitinib (AG 013736)IBA 01/2022
1	trastuzumab deruxtecanIBA 01/2022
1	palbociclibIBA 01/2022
1	human ERBB2 proteinIBA 01/2022
1	avelumabIBA 01/2022
1	alectinibIBA 10/2021
1	IpilimumabIBA 09/2021
1	Gemcitabine FDA Link 02/2021
1	Docetaxel (Taxotere)FDA Link 02/2021
1	rociletinibIBA 02/2021
1	tyrosine receptor (receptor, tyrosine)IBA 01/2021
1	DV281IBA 01/2021
1	veliparibIBA 01/2021
1	Carboplatin (JM8)FDA LinkGeneric 01/2021
1	mobocertinibIBA 01/2021
1	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2020
1	Bevacizumab (Avastin)FDA Link 10/2019
1	eosinylphosphatidylethanolamine (EOPE)IBA 01/2019
1	agerafenibIBA 01/2019
1	Cetuximab (Erbitux)FDA Link 01/2018
1	Neoplasm Antigens (Tumor Antigens)IBA 01/2018
1	insulin receptor tyrosine kinaseIBA 01/2017
1	3- (8- amino- 1- (2- phenylquinolin- 7- yl)imidazo(1,5- a)pyrazin- 3- yl)- 1- methylcyclobutanolIBA 01/2017
1	SteroidsIBA 12/2016
1	vinyltriethoxysilane (VTES)IBA 02/2015
1	Thromboplastin (Tissue Factor)IBA 02/2015
1	Cyclin-Dependent Kinases (cdk Proteins)IBA 01/2015
1	Monoclonal AntibodiesIBA 12/2014
1	Membrane Glycoproteins (Membrane Glycoprotein)IBA 12/2014
1	amatuximabIBA 12/2014
1	Cisplatin (Platino)FDA LinkGeneric 12/2014

Therapy/Procedure

18	Therapeutics 03/2022 - 02/2006
8	Drug Therapy (Chemotherapy) 01/2022 - 09/2014
5	Radiotherapy 01/2018 - 04/2011
4	Immunotherapy 09/2021 - 01/2017
1	Chemoradiotherapy 01/2021
1	Precision Medicine 10/2017